Background Donors other than matched siblings and low-intensity conditioning regimens are increasingly used in haematopoietic stem cell transplantation. We aimed to compare the relative risk of donor type and conditioning regimen intensity on the transplantation outcomes of in patients with sickle cell disease.
Introduction
Sickle cell disease is the most common inherited haemoglobinopathy and occurs in one in 500 African-American and one in 1000-1400 Hispanic-American births. Worldwide, over 270 000 affected infants are born annually. For children with access to modern health care, overall survival at 18 years of age is 85·6% (73·4-97·8). 1 The life expectancy of adults with sickle cell disease is shortened by at least two decades compared to the general population. 2, 3 Risk factors associated with mortality in adults include age, gender, elevated tricuspid valve regurgitation velocity, intensity of haemolytic anaemia, and elevated blood concentrations of ferritin, creatinine, and aspartate transaminase. 3, 4 Haematopoietic cell transplantation is potentially curative for sickle cell disease but the treatment itself is associated with substantial risks which can limit its use. Although the probability of overall survival is approximately 90% at 5 years after transplantation in recipients of a human leukocyte antigen (HLA)-matched sibling transplant, [5] [6] [7] [8] access is limited by donor availability. As a result, alternative donor sources have been explored. Because of the rarity of HLA haplotypes observed in patients of African-descent, matched unrelated donors are infrequent, 9 therefore grafts from haploidentical related or mismatched unrelated donors often have to be used. [10] [11] [12] [13] Treatment failure is primarily attributed to graft failure after transplantations from mismatched related donors 10 and to development of chronic graft-versus-host disease (GVHD) after transplantation from matched unrelated donors. 11 Data reported to the Center for International Blood and Marrow Transplant Research (CIBMTR) indicate increasing numbers of transplantations from alternative donors, in particular for young adults, and the use of conditioning regimens that are not full intensity (ie, myeloablation) in the USA. Therefore, this study sought to compare the relative risks of donor type and conditioning regimen intensity on outcomes after allogeneic transplantation for sickle cell disease in 2008-17, a period during which alternative donors and reduced intensity and non-myeloablative conditioning regimens were increasingly used for transplantation.
Methods

Study design and participants
The CIBMTR is a working group of more than 300 transplant centres worldwide that contribute data on consecutive allogeneic and autologous transplantations for different indications. Patients are followed longitudinally until death or lost to follow-up. Accuracy of data reported to the CIBMTR and compliance are monitored by on-site audits. Consent for research is sought from patients or their legal guardians. The Institutional Review Board of the National Marrow Donor Program approved this study.
We retrospectively reviewed data from 90 US centres reported to the CIBMTR. We included patients younger than 50 years (7 patients aged 50 years or older were excluded, this group are more likely to have transplantrelated complications including death), who had genetically confirmed sickle cell disease (Hb SS) or sickle beta thalassemia (Hb Sβ), and underwent allogeneic haematopoietic cell transplantation between Jan 15, 2008, and Dec 28, 2017, including transplants from HLAmatched sibling donors, haploidentical related donors, matched unrelated donors, or mismatched unrelated donors.
We excluded patients from two transplant centres that failed data accuracy audit, including patients who received conditioning regimens rarely used for sickle cell disease (ie, off-label regimens containing treosulfan and total body irradiation [TBI] ≥1000 cGy), patients who did not receive prophylaxis for GVHD, and patients who were inadequately followed up after transplantation.
Procedures
We retrieved the following information for all eligible patients from the CIBMTR: donor type (patients were grouped by donor type, including HLA-matched sibling, haploidentical related donors, and HLA-matched and mismatched unrelated donors, and donor-recipient pairs
Research in context
Evidence before the study We searched MEDLINE from Jan 1, 2011, to Aug 29, 2018, for articles on sickle cell disease published after 2010, with the search terms "sickle cell disease", "HLA-matched sibling", "haploidentical", "unrelated", and "transplant". In addition to two reports of transplantations from HLA-matched sibling donors, we identified five reports of transplantations from haploidentical and unrelated donors but they were limited to small numbers of patients. We did not identify any reports that compared outcomes after transplantations from HLA-matched siblings, haploidentical donors, or unrelated donors in patients with sickle cell disease. Furthermore, the heterogeneity of transplant conditioning regimens in the reports made it impossible to assess the effect of conditioning regimen intensity on transplantation outcomes for patients with sickle cell disease.
Added value of the study
To our knowledge this is the first study to compare transplant outcomes by donor type for sickle cell disease. In a population of 910 patients we recorded improved event-free survival and overall survival for patients who received transplantation from HLA-matched siblings compared to other allogeneic transplantation types. The occurrence of graft failure was increased after transplantation from alternative donors compared with transplantations from HLA-matched sibling.
Implications of all the available evidence
There are publications with fewer than 30 patients that have reported outcomes using alternative donors but not a direct comparison as we have undertaken. A direct comparison of available donor types has offered an unique opportunity to address barriers to success after alternative donor transplantation. Well designed phase 2 trials that investigate strategies to overcome graft failure after transplantation from alternative donor and increased prevalence of graft-versus-host disease after transplantation from unrelated donors are needed.
were HLA-matched at the allele-level [HLA-A, HLA-B, HLA-C, and HLA-DRB1]), conditioning regimen intensity (myeloablative, non-myeloablative, and reduced-intensity regimens), age, sex, performance score (Lansky play scale or Karnofsky performance score), comorbidity index (hematopoietic cell transplant comorbidity index score), recipient cytomegalovirus serostatus, graft type (bone marrow, peripheral blood, or umbilical cord blood), and transplantation period (2008-12 and 2013-2017) .
Conditioning regimen for patients was either myeloablative, reduced intensity, or non-myeloablative, and was established on the basis of previously defined criteria. 14 Briefly, regimens were considered myeloablative when busulfan was administered orally at a concentration greater than 8 mg/kg or intravenously at a concentration greater than 6 mg/kg, or melphalan was administered at concen trations greater than 150 mg/m². Regimens using lower doses of busulfan or melphalan (administered without another alkylating agent) were considered reduced intensity. TBI regimens (dose 200-400 cGy) were considered non-myeloablative. Myeloablative conditioning is the regimen with highest intensity and non-myeloablative is the one with lowest intensity, whereas the reduced-intensity regimens fall into an intermediate intensity category that does not fit the definition of myeloablative or non-myeloablative conditioning.
The main outcome measure was event-free survival (defined as time from transplantation to death or graft failure) assessed throughout the entire follow-up period. Graft failure was defined as: failure to achieve an absolute neutrophil recovery (ANC) of 0·5 × 10⁹ cells per L or more for 3 consecutive days; a decline in ANC to less than 0·5 × 10⁹ cells per L without recovery, after having achieved an ANC 0·5 × 10⁹ cells per L or more; myeloid donor chimerism (<5%); or second transplant. 15 Our definition of graft failure considered donor chimerism information collected up to 2 years after transplantation. Thereafter, our standardised data-collection forms asked whether the patient experienced graft failure (<5% donors) and the date of failure.
Other outcomes studied were overall survival (death from any cause was considered an event) assessed throughout the entire follow-up period, and acute and chronic GVHD graded using standard criteria (modified Glucksberg grading for acute GVHD and National Institute of Health criteria for chronic GVHD). 16, 17 GVHD is an immunologically mediated complication of transplantation affecting multiple organs. Acute GVHD occurs primarily within the first 3 months after transplantation and chronic GVHD ensues thereafter. Occurrence of acute GVHD of grade 2-4 and any chronic GVHD were considered events.
Statistical analysis
The characteristics of patients grouped by donor type were compared using the χ² test for categorical variables. The proportion of patients with graft failure and acute and chronic GVHD were calculated using the cumu lative incidence estimator to accommodate competing risks (ie, death). 18 Risk factors associated with event-free survival, overall survival, graft failure, and acute and chronic GVHD were examined using the Cox proportional hazards model; 19 hazard ratios (HRs) and their associated 95% CIs were estimated for all outcomes. The probabilities of event-free survival and overall survival were generated from final Cox regression models. 20 Surviving patients were censored at last follow-up.
Variables considered were age, sex, performance score, comorbidity index, recipient cytomegalovirus serostatus, donor type, conditioning regimen intensity, graft type, and transplantation period (2008-12 vs 2013-17, chosen arbitrarily). Age was treated as a binary variable (≤12 years vs 13-49 years). The age cutoff at 13 years was determined statistically using the minimum p-value approach. To determine the optimal age cutoff, we used a series of twosample tests for multiple possible candidate dichotomisations of age. For each candidate cutoff, an appropriate Cox model with a single binary covariate for age was constructed and the p value for the Wald test was obtained. The optimal age cutoff was defined as that candidate cutoff with the smallest p value. All variables met the assumption of proportional hazards and there were no first-order interactions between the variables held in Cox models.
The level of significance set for the study was p less than 0·05. All p values are two-sided and all analyses were done using SAS version 9.4.
Role of the funding source
The funder of the study played no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.
Results
Of 1417 patients with sickle cell disease who had a transplantation reported to the CIBMTR, 996 (70%) underwent transplantation during the period of interest, of whom 910 (91%) were eligible for this study (figure 1). We excluded 43 (4%) of 996 patients from two transplant centres that failed data accuracy audit: 10 patients received uncommon conditioning regimens (ie, regimens containing treosulfan [n=8] and TBI dose ≥1000 cGy [n=2]), 13 did not receive prophylaxis for GVHD, and 20 (2%) were inadequately followed up after transplantation.
Treosulfan can only be used as an investigational new drug in the USA and high-dose TBI (≥1000 cGy) regimens are rarely used for sickle cell disease. 185 (20%) of these 910 patients were included in earlier reports 7 There were no differences in sex distribution or recipient cytomegalovirus serostatus between the groups. However, recipients of transplants from HLA-matched siblings and from HLA-matched and HLA-mismatched unrelated donors were younger and more likely to have performance scores of 90 or 100 and a HCT-comorbidity index of 0-2 than recipients of transplants from haploidentical related (table 1) . Event-free survival was decreased in patients aged 13 years or older versus those aged 12 years or younger (HR 1·74, 1·24-2·45), in those who received reducedintensity conditioning regimens versus non-myeloablative regimens (1·97, 1·15-3·36), and after transplantation of grafts from donors who were not HLA-matched siblings versus HLA-matched siblings (5·30, 3·17-8·86, for haploidentical related donors; 3·71, 2·39-5·75, for HLAmatched unrelated donors; and 4·34, 2·58-7·32, for HLAmismatched unrelated donors; table 2 and figure 2A ). Event-free survival did not differ between myeloablative and reduced-intensity regimens (0·80, 0·56-1·13; p=0·21), between HLA-matched unrelated donors and haploidentical related (1·43, 0·81-2·50; p=0·21) or mismatched unrelated (1·17, 0·67-2·05; p=0·58) donors, or between mismatched unrelated and haploidentical related donors (1·22, 0·65-2·27; p=0·98). 3-year eventfree survival is shown in the appendix (p 1).
Donor type was associated with graft failure. Compared with recipients of transplants from HLA-matched sibling the proportion of patients with graft failure increased among recipients of transplants from haploidentical relatives (HR 6·58, 95% CI 3·55-12·21) and HLAmatched (2·88, 1·54 -5·37) and HLA-mismatched (4·38, 2·31-8·31) unrelated donors (table 2, figure 2B ). Graft failure occurred in a greater proportion of recipients of transplants from haploidentical relatives (2·27, 1·09-4·76; p=0·028), but not HLA-mismatched unrelated donors (1·52, 0·71-3·24; p=0·28), than from HLAmatched unrelated donors. Graft failure did not differ between mismatched unrelated and haploidentical related donor transplants (0·67, 0·31-1·44; p=0·30). Graft failure occurred less frequently in women than in men (0·61, 0·42 -0·90; table 2). The proportion of patients with graft failure at 3 years is shown in the appendix (p 1).
Overall survival was lower in patients aged 13 years or older than in those younger than 13 years (HR 3·15, 95% CI 1·86-5·34), in those who received myeloablative (4·62, 1·87-11·44) and reduced-intensity (3·79, 1·46-9·84) conditioning than in those who received nonmyeloablative regimens, and after transplantation of grafts from donors who were not HLA-matched siblings than HLA-matched siblings (2·94, 1·26-6·87, for haploidentical related donors; 5·12, 2·79-9·40, for HLAmatched unrelated donors; and 4·88, 2·22-10·75, for HLA-mismatched unrelated donors; table 2, figure 2C ). Overall survival did not differ between myeloablative and reduced intensity regimens (1·22, 0·74-2·02; p=0·44). Compared with recipients of transplants from HLAmatched unrelated donors, overall survival did not differ in recipients of transplants from haploidentical related donors (0·57, 0·24-1·35; p=0·20) or from mismatched unrelated donors (0·95, 0·44-2·05; p=0·90). Similarly, overall survival did not differ between mismatched unrelated donors and haploidentical related donors (0·60, 0·24-1·49; p=0·27). 3-year overall survival is shown in the appendix (p 1).
The proportion of patients with acute GVHD was increased with myeloablative (HR 4·14, 95% CI 1·68-10·22) and reduced-intensity (4·43, 1·73-11·35) conditioning versus non-myeloablative regimens; after transplantation of grafts from haploidentical related donors (2·27, 1·08-4·77), HLA-matched unrelated donors (3·84, 2·22-6·63), and HLA-mismatched unrelated donors (6·14, 3·66-10·28) versus HLAmatched siblings, and in the transplantation period 2013-17 (1·74, 1·06-2·84) versus 2008-12 (table 3) . The proportion of patients with acute GVHD at 100 days is shown in the appendix p 1.
Acute GVHD risks did not differ between myeloablative and reduced-intensity conditioning regimens (0·93, 0·60-1·46; p=0·77). The risk of acute GVHD did not differ between transplants from HLA-matched unrelated donors and recipients of transplants from haploidentical related donors (0·63, 0·27-1·47; p=0·29) or mismatched unrelated donors (1·27, 0·62-2·59, p=0·51), or between recipients of transplants from HLA-mismatched unrelated donors and from haploidentical related donors (0·37, 0·20-1·20; p=0·12). The severity of acute GVHD did not differ by donor type (p=0·35; data not shown).
The proportion of patients with chronic GVHD was increased in patients aged 13 years or older versus those younger than 13 years (HR 1·46, 95% CI 1·06-2·00), those treated with myeloablative (2·82, 1·51-5·27) and reduced-intensity (4·00, 2·11-7·55) conditioning versus non-myeloablative regimens, and those who received a transplant from an HLA-matched unrelated donor (1·70, 1·14-2·54) versus an HLA-matched sibling ( after reduced intensity compared with myeloablative conditioning regimens (1·41, 1·03-1·96; p=0·031). The risk of chronic GVHD did not differ between recipients of transplants from HLA-matched unrelated donors and haploidentical related donors (1·03, 0·54-1·96, p=0·93) or HLA-mismatched unrelated donors (0·93, 0·52-1·67, p=0·82), or between recipients of transplants from HLAmismatched unrelated and from haploidentical related donors (1·09, 0·54-2·22, p=0·79). The severity of chronic GVHD did not differ by donor type (p=0·12; data not shown). The proportion of patients with chronic GVHD at 3 years is shown in the appendix p 1.
A subset analysis of 558 recipients of transplants from HLA-matched sibling was done to assess the effect of conditioning regimen intensity. Conditioning regimen intensity was not associated with overall sur vival. However, prevalence of graft failure increased after reducedintensity conditioning compared with myelo ablative (HR 0·28, 95% CI 0·13-0·57; p<0·0001) and non-myeloablative (0·29, 0·08-1·00; p=0·049) regimens. Consequently, event-free survival was decreased after reduced-intensity conditioning com pared with myeloablative (0·38, 0·21-0·67; p=0·00080) and non-myeloablative (0·36, 0·13-0·94; p=0·036) regimens. Consistent with the main analysis, the HR for overall survival was three-times higher in patients aged 13 years or older (3·25, 1·27-8·29, p=0·014) than in those younger than 13 years.
Six ( virus-positive lymphoproliferative disease at a median of 5 months (IQR 3-12) after transplantation with all having had in-vivo T-cell depletion with anti-thymocyte globulin or alemtuzumab. Notably, one (<1%) of 421 patients for whom pre-transplantation and post-transplantation sickle cell disease-specific data were available reported acute chest syndrome and six (1%) patients had a stroke; all seven patients had full donor myeloid chimerism.
Discussion
There were two key findings in this retrospective analysis that warrant caution when considering alternative donor transplantation as a potentially curative option for patients with sickle cell disease. Mortality and prevalence of graft failure were increased after any alternative donor transplantation compared with HLA-matched sibling transplantation, which resulted in substantially decreased event-free survival. To our knowledge, this is the first study to assess allogeneic transplantation outcomes for patients with sickle cell disease who received transplantations from HLA-matched sibling donors or transplantations from alternative donors (haploidentical related donors, HLA-matched unrelated donors, and HLA-mismatched unrelated donors). The study also addressed the effect of conditioning regimen intensity on transplant outcomes. Myeloablative and reduced-intensity regimens were associated with increased mortality as well as acute and chronic GVHD. Conditioning regimen intensity was not associated with graft failure. Increased mortality and prevalence of graft failure after transplantation from HLA-mismatched unrelated donors has been reported for non-malignant diseases but those studies 21, 22 did not include many patients who received transplants for haemoglobinopathies. Our findings confirm the adverse effect of HLA disparity on survival outcomes and graft failure after transplantation in patients with sickle cell disease. The timing of graft failure differed by donor type in patients with sickle cell disease. Graft failure after transplantation from HLAmatched siblings and unrelated donors primarily occurred within 1-2 years after transplantation. By contrast, graft failure was more common 2-3 years after haploidentical related donor transplantation. This is particularly relevant in light of the improved outcomes reported in two recent phase 2 trials 23,24 of transplantations from haploidentical related donor with 15 and 12 patients with sickle cell disease. Both trials used the posttransplantation cyclophosphamide approach to overcome the HLA barrier. One trial 23 reported donor engraftment in 14 (93%) of 15 patients at 6 months 23 and the other trial 24 reported full or mixed donor engraftment 11 (92%) of 12 patients in the first year after transplantation. Longer follow-up of these patients is needed to confirm sustained donor engraftment. We did not find an association between graft failure and conditioning regimen tested (myeloablative, reduced intensity, and non-myeloablative). The concept of less intense conditioning regimens (reduced intensity or non-myeloablative) was introduced to overcome mortality risks associated with myeloablation in less fit patients or for diseases for which myeloablation was not desirable. Therefore, the finding that mortality risks were four times higher with both myeloablative and reduced-intensity regimens than with non-myeloablative regimens was unexpected. The recorded increased mortality might be explained in part by the increased risks of acute and chronic GVHD with myeloablative and reduced intensity regimens. These regimens relied on standard GVHD prophylaxis, which included a calcineurin inhibitor alone or with methotrexate, mycophenolate, or sirolimus. The non-myeloablative regimens used a different strategy. In the setting of HLA-matched sibling transplantation, the low-dose TBI approach incorporates an attempt at tolerance induction through the use of lymphocyte reduction with alemtuzumab plus mTOR inhibition with sirolimus during recovery. 25 This tolerance is blocked in vitro and in animal models with calcineurin inhibitor. 25 Similarly, for transplantation from haploidentical related donors, post-transplantation treatment with cyclophosphamide induces early immune tolerance mediated by the destruction of alloreactive donor and recipient T cells, and any remaining alloreactivity is counterbalanced by increasing the number T regulatory cells. 26 A delayed but long-lasting intrathymic clonal deletion of anti-host T cells maintains long-term immune tolerance. 26 Tolerance induction and low prevalence of GVHD associated with low-intensity regimens are likely to have contributed to the high eventfree survival and overall survival in these patients. Increased prevalence of acute GVHD after the 2008-12 period can be explained by the increasing numbers of transplantation from unrelated donors. 27 On the basis of these observations, we hypothesise that immune tolerance induction, rather than regimen intensity per se, is the key driver of survival after transplantation for treatment of sickle cell disease.
Events/patients Hazard
Age at transplantation was an important predictor of survival in this study. The risk of death is three times higher in a patient aged 13 years or older than in a younger patient, assuming the type of donor and conditioning regimen intensity are the same for both patients. Although almost half the study population was aged 13 years or older, we did not find another age cutoff associated with survival differences. Only seven trans plantations were reported in patients aged 50 years or older and they were not included in the current analyses. The effect of age in adults can only be studied properly in a larger adult population than represented in our population, and this is a limitation of our study. The timing of transplantation is dependent on physician and patient choice, donor availability, and access to health care. With the exception of stroke, severity of symptoms of sickle cell disease that prompts referral for transplantation is variable. In the absence of a comparative study of transplant recipients and those receiving non-transplantation therapies with comparable disease severity, we cannot comment on whether transplantation from HLA-matched sibling should be offered in the first decade of life. With 3-year prevalence of chronic GVHD of 18% (95% CI 15-22) after transplantation from HLA-matched siblings we cannot recommend transplantation for asymptomatic children or for children without severe disease. Consistently with a published study, 28 we did not record an association between comorbidity index and survival.
There are several limitations to our study because of its retrospective nature, which include the fact that the decision to offer transplantation and its timing, choice of conditioning regimen intensity, and choice of alternative donor in the absence of a matched sibling were made by the treating physicians at each participating institution. We acknowledge transplantation strategies are best studied in the setting of multicentre trials. Yet, prospective studies are challenging as accrual can extend over 5 years for funded multicentre transplantation trials. 5, 11 We did not consistently collect information on haemoglobin S concentration after transplantation. Our definition of graft failure considered donor chimerism collected up to 2 years after transplantation. Thereafter, our standardised data-collection forms asked whether the patient experienced graft failure (<5% donors) and the date of failure. We did not have data on red blood cell chimerism.
The occurrence of events such as acute chest syndrome and stroke in the setting of full donor chimerism deserves further study and such research is best achieved through careful longitudinal follow-up focusing on sickle cell disease-related complications. We did not collect detailed data on sickle cell disease-related complications after transplantation to study the occurrence of stroke in patients with full myeloid donor chimerism. Similarly, because of limited follow-up, the recorded increased risk of post-transplantation myeloid malignancy after non-myeloablative regimens should be further investigated. Whether this finding is a result of age, transplantation per se, regimen intensity, or some other unknown or unmeasured factor cannot be addressed in this study. A 2017 study 29 found that the standardised incidence ratio for haematologic cancer in an unselected population with sickle cell disease is 1·72 (95% CI 1·17-2·44) and that patients were diagnosed with their first primary cancer at a median age of 46 years. With increasing numbers of transplantations in young adults, in a few years it might be possible to design comparative studies on cancer prevalence amongst patients with sickle cell disease who received or did not receive transplantation. Although our data does not favour one alternative donor over another, a decrease by 20 percentage points in 3-year event-free survival between recipients of transplants from haploidentical relatives and HLA-matched unrelated donors cannot be ignored. To detect a significant difference with 80% power, 271 patients are needed but our analyses only included 248 patients.
Allogeneic transplantation is potentially curative, but we do not know whether appropriate follow-up might reduce the mortality caused by the transplantation procedure to less than the mortality caused by complications of sickle cell disease. A phase 2 trial (NCT02766465) of young adults with severe sickle cell disease in the USA addresses this question by assigning eligible participants (eligibility criteria are based on disease severity and organ function) to either a donor group (if they have a suitably matched sibling or unrelated donor) or a no-donor group (if they do not have a suitable donor). Participants in the donor group are expected to undergo transplantation and those in the nodonor group are expected to receive best available standard of care. We acknowledge monetary coverage for access to health care is critical to improve survival. Access to transplantation for young adults with sickle cell disease is also challenging in the USA. The introduction of the Coverage with Evidence Determination programme by the Center for Medicare and Medicaid Services is likely to broaden access to allogeneic transplantation. Another potentially curative treatment for sickle cell disease that is being pursued is the use of a lentiviral vector to add an anti-sickling β-globin gene variant into autologous haematopoietic cells. 30 This approach is being studied in small numbers of patients and definitive conclusions will require confirmation of success in larger numbers of patients as well as longer follow-up.
In conclusion, our data suggest that event-free survival is improved in patients with sickle cell disease who receive an allogenic transplantation at age 12 years or younger and those with an HLA-matched sibling donor. For patients without a matched sibling donor available, our data do not favour one alternative donor type over another in this setting. Transplantation from alternative donors broadens access to this treatment. However, strategies aimed at lowering graft failure and GVHD are needed before transplantation from these donors can be as effective as that from HLA-matched siblings.
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